LODESTAR: Rucaparib in HRD Mutated Solid Tumors
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

LODESTAR: Rucaparib in HRD Mutated Solid Tumors

Sponsor: Clovis Oncology, Inc.

Protocol CO-338-100. A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated with Deleterious Mutations in Homologous Recombination Repair Genes. Single agent, PARP inhibitor rucaparib for patients with a solid tumor that has a mutation in any of the following genes: BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B.